Acorda Therapeutics Stock Price, News & Analysis (NASDAQ:ACOR)

$21.30 0.75 (3.65 %)
(As of 12/13/2017 04:00 PM ET)
Previous Close$20.55
Today's Range$20.55 - $21.85
52-Week Range$13.60 - $33.00
Volume442,951 shs
Average Volume924,629 shs
Market Capitalization$953.64 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58

About Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics logoAcorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ACOR
CUSIP00484M10
Phone914-347-4300

Debt

Debt-to-Equity Ratio0.49%
Current Ratio2.77%
Quick Ratio2.40%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$519.60 million
Price / Sales1.92
Cash FlowN/A
Price / CashN/A
Book Value$14.40 per share
Price / Book1.48

Profitability

Trailing EPS($1.21)
Net Income$-34,610,000.00
Net Margins-10.25%
Return on Equity-8.18%
Return on Assets-4.15%

Miscellaneous

Employees597
Outstanding Shares46,750,000

Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) posted its quarterly earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.43 EPS for the quarter, missing the Zacks' consensus estimate of $0.69 by $0.26. The biopharmaceutical company had revenue of $141.07 million for the quarter, compared to analysts' expectations of $150.64 million. Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The company's quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.04) EPS. View Acorda Therapeutics' Earnings History.

When will Acorda Therapeutics make its next earnings announcement?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Acorda Therapeutics.

Where is Acorda Therapeutics' stock going? Where will Acorda Therapeutics' stock price be in 2017?

14 equities research analysts have issued twelve-month price objectives for Acorda Therapeutics' stock. Their forecasts range from $13.00 to $34.00. On average, they expect Acorda Therapeutics' share price to reach $20.77 in the next year. View Analyst Ratings for Acorda Therapeutics.

What are Wall Street analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:

  • 1. Cantor Fitzgerald analysts commented, "Not what ACOR stock needed. ACOR announced this morning that an increase in blood monitoring for agranulocytosis is being implemented for subjects in the Phase 3 trial of tozadenant in Parkinson’s disease (PD)." (11/15/2017)
  • 2. According to Zacks Investment Research, "Acorda missed expectations for both earnings and revenue in the third-quarter of 2017. The company’s key multiple sclerosis drug Ampyra is facing patent challenges in the United States. Hence, Acorda’s dependence on Ampyra for a major part of its revenue is concerning. However, Ampyra showed sequential improvements. The company has its share of pipeline setbacks too with discontinuation of a few late stage programs. Acorda is working on strengthening its Parkinson’s pipeline by focusing on two late stage candidates tozadenant and Inbrija (formerly known as CVT-301) in its portfolio. However, Inbrija recently received a refusal to file letter from the FDA which is concerning as it would delay its commercial launch. The company’s share price has significantly outperformed the industry so far this year. The company is also working on expanding its pipeline by entering into deals and pursuing acquisitions." (11/6/2017)
  • 3. Stifel Nicolaus analysts commented, "Alexion (ALXN) reported 2Q17 sales/earnings and provided a business update (PDF) to investors. The company had a strong 2Q17, reporting sales of $912M and non-GAAP EPS of $1.56, beating OPCO by 9% and 25% respectively. The strong beat was partially attributable to favorable one-offs in 1H17, with 2H17 expected to see weaker growth, which was well flagged by the company. The pipeline keeps moving along with a positive opinion for Soliris rMG in the EU in June and a PDUFA date of Oct. 23, 2017. We were particularly struck by new management’s ability to stabilize the business, provide transparency and the continuing strong fundamentals." (7/28/2017)
  • 4. Cowen Inc analysts commented, "ACOR released Q4 Ampyra revenue and provided 2017 Ampyra guidance, both just." (1/9/2017)

Who are some of Acorda Therapeutics' key competitors?

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the folowing people:

  • Ron Cohen M.D., President,Chief Executive Officer, Director (Age 61)
  • Richard P. Batycky Ph.D., Chief Technology Officer and Site Head (Age 49)
  • David Lawrence, Chief Business Operations, Principal Accounting Officer (Age 59)
  • Andrew R. Blight Ph.D., Chief Scientific Officer (Age 66)
  • Jane Wasman J.D., President - International, General Counsel, Corporate Secretary (Age 61)
  • Burkhard Blank M.D., Chief Medical Officer (Age 62)
  • Andrew Hindman, Chief Business Development Officer (Age 44)
  • Lauren M. Sabella, Chief Commercial Officer (Age 56)
  • Barry E. Greene, Independent Director (Age 53)
  • Peder K. Jensen M.D., Independent Director (Age 62)

Who owns Acorda Therapeutics stock?

Acorda Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (5.68%), Macquarie Group Ltd. (1.47%), Principal Financial Group Inc. (0.76%), Cambiar Investors LLC (0.69%), Schwab Charles Investment Management Inc. (0.60%) and Prudential Financial Inc. (0.35%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Richard P Batycky, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.

Who sold Acorda Therapeutics stock? Who is selling Acorda Therapeutics stock?

Acorda Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Cambiar Investors LLC, Schwab Charles Investment Management Inc., Cornerstone Capital Management Holdings LLC., Prudential Financial Inc., SG Americas Securities LLC, California State Teachers Retirement System, Pinebridge Investments L.P. and Great West Life Assurance Co. Can. Company insiders that have sold Acorda Therapeutics company stock in the last year include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence, Lorin Randall and Ron Cohen. View Insider Buying and Selling for Acorda Therapeutics.

Who bought Acorda Therapeutics stock? Who is buying Acorda Therapeutics stock?

Acorda Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, OxFORD Asset Management LLP, Macquarie Group Ltd., Convergence Investment Partners LLC, KBC Group NV, Pictet Asset Management Ltd., Nationwide Fund Advisors and GSA Capital Partners LLP. Company insiders that have bought Acorda Therapeutics stock in the last two years include Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.

How do I buy Acorda Therapeutics stock?

Shares of Acorda Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of Acorda Therapeutics stock can currently be purchased for approximately $21.30.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $953.64 million and generates $519.60 million in revenue each year. The biopharmaceutical company earns $-34,610,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Acorda Therapeutics employs 597 workers across the globe.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.


MarketBeat Community Rating for Acorda Therapeutics (ACOR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  321 (Vote Underperform)
Total Votes:  560
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Acorda Therapeutics (NASDAQ:ACOR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.232.302.44
Ratings Breakdown: 2 Sell Rating(s)
10 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.77$27.33$26.50$28.00
Price Target Upside: 3.85% upside4.60% downside35.55% upside82.41% upside

Acorda Therapeutics (NASDAQ:ACOR) Consensus Price Target History

Price Target History for Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics (NASDAQ:ACOR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/28/2017Piper Jaffray CompaniesReiterated RatingNeutral$22.00LowView Rating Details
11/20/2017HC WainwrightSet Price TargetBuy$34.00N/AView Rating Details
11/17/2017CowenReiterated RatingBuy$30.00N/AView Rating Details
11/16/2017Janney Montgomery ScottSet Price TargetHold$26.00 -> $17.00N/AView Rating Details
11/16/2017Raymond James FinancialDowngradeMarket Perform -> Underperform$7.00 -> $13.00N/AView Rating Details
11/16/2017Stifel NicolausDowngradeBuy -> Hold$26.00 -> $15.00N/AView Rating Details
11/15/2017J P Morgan Chase & CoLower Price TargetNeutral$19.00N/AView Rating Details
11/15/2017Leerink SwannLower Price TargetMarket Perform$18.00N/AView Rating Details
11/15/2017OppenheimerSet Price TargetHold$18.00N/AView Rating Details
11/15/2017Cantor FitzgeraldLower Price TargetNeutral$18.00 -> $16.00N/AView Rating Details
11/9/2017CIBCInitiated CoverageMarket Perform -> Market PerformN/AView Rating Details
11/1/2017Jefferies GroupBoost Price TargetHold$22.00 -> $25.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingSell -> Sell$20.00N/AView Rating Details
1/8/2017Evercore ISISet Price TargetHold$23.00N/AView Rating Details
6/1/2016AegisBoost Price TargetBuy$40.00 -> $52.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Acorda Therapeutics (NASDAQ:ACOR) Earnings History and Estimates Chart

Earnings by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics (NASDAQ ACOR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018$1.00N/AView Earnings Details
10/31/2017Q3 2017$0.69$0.43$150.64 million$141.07 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.13$0.29$139.81 million$139.40 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.16)($0.08)$127.34 million$119.39 millionViewN/AView Earnings Details
2/14/2017Q416($0.18)$0.05$137.90 million$140.63 millionViewListenView Earnings Details
10/27/2016Q316($0.26)($0.04)$134.01 million$135.61 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.07$128.33 million$127.45 millionViewListenView Earnings Details
4/28/2016Q116$0.08$0.07$115.36 million$115.90 millionViewListenView Earnings Details
2/11/2016Q415$0.22$0.28$128.24 million$130.90 millionViewListenView Earnings Details
10/22/2015Q315$0.15$0.31$115.52 million$148.20 millionViewListenView Earnings Details
7/30/2015Q215($0.01)$0.31$110.84 million$113.70 millionViewListenView Earnings Details
4/30/2015Q115$0.03($0.02)$100.20 million$99.85 millionViewN/AView Earnings Details
2/12/2015Q414$0.15$0.33$110.80 million$117.90 millionViewN/AView Earnings Details
10/30/2014Q314$0.04$0.34$94.70 million$106.00 millionViewN/AView Earnings Details
7/31/2014Q214$0.14$0.24$91.40 million$97.13 millionViewN/AView Earnings Details
5/6/2014Q114$0.04$0.08$81.30 million$80.52 millionViewN/AView Earnings Details
2/19/2014Q413$0.18$0.32$89.96 million$92.59 millionViewN/AView Earnings Details
10/31/2013Q313$0.13$0.36$90.01 million$84.92 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.09$0.25$82.57 million$87.05 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.20$0.09$80.77 million$71.90 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.15$0.24$78.90 million$81.47 millionViewListenView Earnings Details
10/31/2012Q312$0.10$0.38$75.20 million$77.44 millionViewN/AView Earnings Details
7/31/2012$0.27$0.27ViewN/AView Earnings Details
5/3/2012$0.27$0.36ViewN/AView Earnings Details
2/16/2012$0.24$0.40ViewN/AView Earnings Details
11/4/2011$0.82$0.47ViewN/AView Earnings Details
8/1/2011$0.10$0.01ViewN/AView Earnings Details
5/5/2011$0.17($0.02)ViewN/AView Earnings Details
2/17/2011$0.17$0.09ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Acorda Therapeutics (NASDAQ:ACOR) Earnings Estimates

2017 EPS Consensus Estimate: $1.42
2018 EPS Consensus Estimate: $0.78
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172($0.03)$0.26$0.12
Q3 20172$0.21$0.56$0.39
Q4 20173$0.32$1.68$0.92
Q1 20181$0.69$0.69$0.69
Q2 20181$0.84$0.84$0.84
Q3 20181($0.10)($0.10)($0.10)
Q4 20181($0.65)($0.65)($0.65)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Acorda Therapeutics (NASDAQ:ACOR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Acorda Therapeutics (NASDAQ ACOR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.90%
Insider Trades by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics (NASDAQ ACOR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017Burkhard BlankInsiderSell11,050$20.53$226,856.50View SEC Filing  
10/9/2017David LawrenceInsiderSell250$25.40$6,350.00View SEC Filing  
8/29/2017Scopia Capital Management LpMajor ShareholderBuy766,201$19.23$14,734,045.23View SEC Filing  
8/1/2017Barry E GreeneDirectorSell10,000$21.57$215,700.00View SEC Filing  
7/31/2017Lorin RandallDirectorSell10,000$21.66$216,600.00View SEC Filing  
6/16/2017Ron CohenInsiderBuy20,000$16.95$339,000.00View SEC Filing  
5/15/2017Andrew A HindmanInsiderSell7,704$15.75$121,338.00View SEC Filing  
12/14/2016Ron CohenInsiderSell40,172$20.75$833,569.00View SEC Filing  
10/21/2016Richard P BatyckyInsiderSell2,063$20.30$41,878.90View SEC Filing  
10/7/2016David LawrenceInsiderSell250$20.82$5,205.00View SEC Filing  
10/3/2016Jane WasmanInsiderSell3,750$20.78$77,925.00View SEC Filing  
9/23/2016Jane WasmanInsiderSell500$27.32$13,660.00View SEC Filing  
6/22/2016David LawrenceInsiderSell500$25.09$12,545.00View SEC Filing  
6/8/2016Steven M RauscherDirectorSell1,086$27.83$30,223.38View SEC Filing  
5/13/2016Andrew A HindmanInsiderSell4,860$26.11$126,894.60View SEC Filing  
4/19/2016Lorin RandallDirectorSell1,488$28.68$42,675.84View SEC Filing  
1/4/2016Ian F. SmithDirectorSell13,231$41.85$553,717.35View SEC Filing  
12/23/2015Jane WasmaninsiderSell10,751$43.10$463,368.10View SEC Filing  
12/22/2015Lauren M. SabellainsiderSell7,113$42.04$299,030.52View SEC Filing  
12/21/2015Jane WasmanInsiderSell817$42.00$34,314.00View SEC Filing  
12/18/2015David LawrenceinsiderSell39,026$40.63$1,585,626.38View SEC Filing  
12/17/2015Lauren M. SabellainsiderSell14,229$40.00$569,160.00View SEC Filing  
12/1/2015Enrique J CarrazanaInsiderSell7,218$38.08$274,861.44View SEC Filing  
12/1/2015Ron CohenCEOSell11,850$38.08$451,248.00View SEC Filing  
10/19/2015Andrew BlightinsiderSell32,500$30.87$1,003,275.00View SEC Filing  
10/7/2015Michael W. RogersCFOSell5,700$30.24$172,368.00View SEC Filing  
10/5/2015Jane WasmaninsiderSell3,750$31.75$119,062.50View SEC Filing  
10/5/2015Ron CohenCEOSell135,000$28.03$3,784,050.00View SEC Filing  
9/21/2015Andrew BlightinsiderSell13,085$31.30$409,560.50View SEC Filing  
5/15/2015Andrew A HindmanInsiderSell4,779$29.82$142,509.78View SEC Filing  
1/12/2015Enrique J CarrazanaInsiderSell97,993$42.21$4,136,284.53View SEC Filing  
12/18/2014David LawrenceInsiderSell27,109$40.11$1,087,341.99View SEC Filing  
12/18/2014John P KelleyDirectorSell10,000$40.00$400,000.00View SEC Filing  
12/1/2014David LawrenceInsiderSell8,898$35.60$316,768.80View SEC Filing  
12/1/2014Lauren M SabellaVPSell3,242$35.58$115,350.36View SEC Filing  
12/1/2014Michael W RogersCFOSell230$35.58$8,183.40View SEC Filing  
12/1/2014Ron CohenCEOSell34,394$35.59$1,224,082.46View SEC Filing  
10/7/2014Michael W RogersCFOSell5,700$33.10$188,670.00View SEC Filing  
10/3/2014Jane WasmanInsiderSell3,750$34.13$127,987.50View SEC Filing  
9/24/2014Jane WasmanInsiderSell14,923$36.00$537,228.00View SEC Filing  
8/27/2014Jane WasmanInsiderSell14,923$33.00$492,459.00View SEC Filing  
12/5/2013Lauren SabellaVPSell8,797$31.81$279,832.57View SEC Filing  
12/2/2013Enrique CarrazanaInsiderSell1,640$33.56$55,038.40View SEC Filing  
10/15/2013Enrique J CarrazanaInsiderSell3,333$32.38$107,922.54View SEC Filing  
10/3/2013Jane WasmanInsiderSell3,750$35.74$134,025.00View SEC Filing  
8/20/2013Ron CohenCEOSell149,000$34.10$5,080,900.00View SEC Filing  
8/2/2013John KelleyDirectorSell15,000$38.00$570,000.00View SEC Filing  
7/19/2013Andrew BlightInsiderSell19,296$37.82$729,774.72View SEC Filing  
6/10/2013Ron CohenCEOSell11,000$34.15$375,650.00View SEC Filing  
5/8/2013Sandra Phd PanemDirectorSell10,000$33.80$338,000.00View SEC Filing  
12/4/2012Lauren M SabellaVPSell4,364$24.58$107,267.12View SEC Filing  
12/3/2012Andrew BlightInsiderSell7,200$24.20$174,240.00View SEC Filing  
12/3/2012David LawrenceCFOSell9,313$24.21$225,467.73View SEC Filing  
12/3/2012Ron CohenCEOSell16,407$24.22$397,377.54View SEC Filing  
11/13/2012Sandra Phd PanemDirectorSell22,569$24.12$544,364.28View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Acorda Therapeutics (NASDAQ ACOR) News Headlines

Source:
DateHeadline
ACOR Crosses Above Key Moving Average LevelACOR Crosses Above Key Moving Average Level
www.nasdaq.com - December 13 at 3:23 PM
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Acorda Therapeutics, Inc. Shareholders and ... - Business Wire (press release)The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Acorda Therapeutics, Inc. Shareholders and ... - Business Wire (press release)
www.businesswire.com - December 13 at 7:37 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACORINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACOR
finance.yahoo.com - December 13 at 7:37 AM
ACOR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving ... - Business Wire (press release)ACOR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving ... - Business Wire (press release)
www.businesswire.com - December 12 at 7:39 AM
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Acorda Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of January 17, 2018The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Acorda Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of January 17, 2018
finance.yahoo.com - December 12 at 7:39 AM
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Acorda Therapeutics, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action LawsuitSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Acorda Therapeutics, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit
finance.yahoo.com - December 11 at 3:21 PM
Acorda Resubmits NDA for Parkinson's Disease Candidate InbrijaAcorda Resubmits NDA for Parkinson's Disease Candidate Inbrija
finance.yahoo.com - December 9 at 7:34 AM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of Commencement of a ... - Business Wire (press release)EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of Commencement of a ... - Business Wire (press release)
www.businesswire.com - December 8 at 7:46 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018
finance.yahoo.com - December 7 at 3:24 PM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018
finance.yahoo.com - December 7 at 3:24 PM
The Klein Law Firm Announces the Commencement of a Class Action Filed on Behalf of Acorda Therapeutics, Inc ... - Business Wire (press release)The Klein Law Firm Announces the Commencement of a Class Action Filed on Behalf of Acorda Therapeutics, Inc ... - Business Wire (press release)
www.businesswire.com - December 6 at 7:55 AM
Form 4 ACORDA THERAPEUTICS INC For: Dec 01 Filed by: Wasman Jane - StreetInsider.comForm 4 ACORDA THERAPEUTICS INC For: Dec 01 Filed by: Wasman Jane - StreetInsider.com
www.streetinsider.com - December 6 at 7:55 AM
Form 4 ACORDA THERAPEUTICS INC For: Dec 01 Filed by: Wasman JaneForm 4 ACORDA THERAPEUTICS INC For: Dec 01 Filed by: Wasman Jane
www.streetinsider.com - December 5 at 3:23 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018
finance.yahoo.com - December 5 at 3:22 PM
The Klein Law Firm Announces the Commencement of a Class Action Filed on Behalf of Acorda Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of January 17, 2018The Klein Law Firm Announces the Commencement of a Class Action Filed on Behalf of Acorda Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of January 17, 2018
finance.yahoo.com - December 5 at 3:22 PM
Acorda Therapeutics, Inc. (ACOR) Insider Burkhard Blank Sells 11,050 SharesAcorda Therapeutics, Inc. (ACOR) Insider Burkhard Blank Sells 11,050 Shares
www.americanbankingnews.com - December 5 at 8:30 AM
$177.37 Million in Sales Expected for Acorda Therapeutics, Inc. (ACOR) This Quarter$177.37 Million in Sales Expected for Acorda Therapeutics, Inc. (ACOR) This Quarter
www.americanbankingnews.com - December 5 at 7:48 AM
ACT NOW: Monteverde & Associates PC Announces An Investigation of Acorda Therapeutics, Inc. - ACORACT NOW: Monteverde & Associates PC Announces An Investigation of Acorda Therapeutics, Inc. - ACOR
www.prnewswire.com - December 4 at 5:25 PM
ACOR INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Acorda ... - Business Wire (press release)ACOR INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Acorda ... - Business Wire (press release)
www.businesswire.com - December 3 at 7:33 AM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Acorda Therapeutics, Inc. Investors (ACOR) - Business Wire (press release)Glancy Prongay & Murray LLP Commences Investigation on Behalf of Acorda Therapeutics, Inc. Investors (ACOR) - Business Wire (press release)
www.businesswire.com - December 2 at 3:22 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acorda Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – ACORSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acorda Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – ACOR
finance.yahoo.com - December 2 at 8:49 AM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Acorda Therapeutics, Inc. Investors (ACOR)Glancy Prongay & Murray LLP Commences Investigation on Behalf of Acorda Therapeutics, Inc. Investors (ACOR)
finance.yahoo.com - December 2 at 8:49 AM
Acorda Therapeutics, Inc. (ACOR) Given Consensus Recommendation of "Hold" by BrokeragesAcorda Therapeutics, Inc. (ACOR) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 2 at 12:00 AM
IMPORTANT ACORDA THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors who purchased and suffered losses in Acorda Therapeutics, Inc.IMPORTANT ACORDA THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors who purchased and suffered losses in Acorda Therapeutics, Inc.
finance.yahoo.com - December 1 at 3:24 PM
ACOR INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Acorda Therapeutics, Inc. InvestorsACOR INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Acorda Therapeutics, Inc. Investors
finance.yahoo.com - December 1 at 3:24 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acorda Therapeutics, Inc. of Commencement of a ... - Business Wire (press release)INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acorda Therapeutics, Inc. of Commencement of a ... - Business Wire (press release)
www.businesswire.com - December 1 at 8:12 AM
IMPORTANT ACORDA THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP ... - GlobeNewswire (press release)IMPORTANT ACORDA THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP ... - GlobeNewswire (press release)
globenewswire.com - December 1 at 8:12 AM
ACOR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Acorda Therapeutics, Inc. and a Lead Plaintiff Deadline of January 17, 2018ACOR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Acorda Therapeutics, Inc. and a Lead Plaintiff Deadline of January 17, 2018
feeds.benzinga.com - December 1 at 3:53 AM
ACORDA THERAPEUTICS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Acorda Therapeutics, Inc. To Contact The FirmACORDA THERAPEUTICS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Acorda Therapeutics, Inc. To Contact The Firm
finance.yahoo.com - November 30 at 3:22 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline: January 17, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline: January 17, 2018
finance.yahoo.com - November 30 at 3:22 PM
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Acorda Therapeutics, Inc. (Nasdaq: ACOR) To Contact Brower Piven Before The Lead Plaintiff DeadlineSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Acorda Therapeutics, Inc. (Nasdaq: ACOR) To Contact Brower Piven Before The Lead Plaintiff Deadline
finance.yahoo.com - November 30 at 3:22 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acorda Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acorda Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018
finance.yahoo.com - November 30 at 3:22 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acorda Therapeutics, Inc. of a Class Action ... - GlobeNewswire (press release)SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acorda Therapeutics, Inc. of a Class Action ... - GlobeNewswire (press release)
globenewswire.com - November 30 at 7:37 AM
Piper Jaffray Companies Begins Coverage on Acorda Therapeutics (ACOR)Piper Jaffray Companies Begins Coverage on Acorda Therapeutics (ACOR)
www.americanbankingnews.com - November 28 at 8:36 PM
ACOR LOSS NOTICE: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important Deadline in Class ... - Business Wire (press release)ACOR LOSS NOTICE: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important Deadline in Class ... - Business Wire (press release)
www.businesswire.com - November 28 at 3:22 PM
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Acorda Therapeutics, Inc. (ACOR)The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Acorda Therapeutics, Inc. (ACOR)
finance.yahoo.com - November 28 at 3:22 PM
ACOR LOSS NOTICE: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important Deadline in Class Action – ACORACOR LOSS NOTICE: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important Deadline in Class Action – ACOR
finance.yahoo.com - November 28 at 3:22 PM
Robbins Arroyo LLP: Acorda Therapeutics, Inc. (ACOR) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)Robbins Arroyo LLP: Acorda Therapeutics, Inc. (ACOR) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)
www.businesswire.com - November 28 at 7:55 AM
Stock Review for Biotechs Investors -- Spark Therapeutics, Agenus, Coherus Biosciences, and Acorda Therapeutics - PR Newswire (press release)Stock Review for Biotech's Investors -- Spark Therapeutics, Agenus, Coherus Biosciences, and Acorda Therapeutics - PR Newswire (press release)
www.prnewswire.com - November 28 at 7:55 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) and Lead Plaintiff Deadline: January 17, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) and Lead Plaintiff Deadline: January 17, 2018
finance.yahoo.com - November 27 at 3:18 PM
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Acorda Therapeutics, Inc.The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Acorda Therapeutics, Inc.
finance.yahoo.com - November 27 at 3:18 PM
ETFs with exposure to Acorda Therapeutics, Inc. : November 27, 2017ETFs with exposure to Acorda Therapeutics, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 3:18 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acorda Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ACORSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acorda Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ACOR
finance.yahoo.com - November 25 at 3:20 PM
Oppenheimer Holdings Comments on Acorda Therapeutics, Inc.s FY2017 Earnings (ACOR)Oppenheimer Holdings Comments on Acorda Therapeutics, Inc.'s FY2017 Earnings (ACOR)
www.americanbankingnews.com - November 23 at 8:52 AM
Acorda Therapeutics scraps Parkinsons drug after deaths - ReutersAcorda Therapeutics scraps Parkinson's drug after deaths - Reuters
www.reuters.com - November 22 at 9:03 PM
ACORDA THERAPEUTICS INVESTOR DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered ... - Business Wire (press release)ACORDA THERAPEUTICS INVESTOR DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered ... - Business Wire (press release)
www.businesswire.com - November 22 at 9:03 PM
Parkinsons Space in Focus as Acorda Stops Tozadenant TrialParkinson's Space in Focus as Acorda Stops Tozadenant Trial
finance.yahoo.com - November 22 at 4:01 PM
ACOR INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Acorda ...ACOR INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Acorda ...
www.businesswire.com - November 22 at 4:01 PM
Parkinson's Space in Focus as Acorda Stops Tozadenant TrialParkinson's Space in Focus as Acorda Stops Tozadenant Trial
finance.yahoo.com - November 22 at 4:00 PM
Heres Why Acorda Therapeutics Inc Is In Real Trouble Right NowHere's Why Acorda Therapeutics Inc Is In Real Trouble Right Now
feeds.benzinga.com - November 22 at 1:39 PM

SEC Filings

Acorda Therapeutics (NASDAQ:ACOR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Acorda Therapeutics (NASDAQ:ACOR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Acorda Therapeutics (NASDAQ ACOR) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.